Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights
Arcellx reported Q3 2024 financial results and clinical progress for anito-cel in treating relapsed/refractory multiple myeloma. Phase 1 study showed 30.2-month median progression-free survival with 38.1 months median follow-up. Phase 2 iMMagine-1 study demonstrated 95% overall response rate and 62% complete response rate in 58 patients at 10.3 months median follow-up. No delayed neurotoxicities were observed in over 140 treated patients. The company reported $676.7 million in cash and equivalents, expected to fund operations into 2027. Q3 collaboration revenue increased to $26.0 million, while net loss decreased to $25.9 million.
Arcellx ha riportato i risultati finanziari del Q3 2024 e i progressi clinici per anito-cel nel trattamento del mieloma multiplo recidivante/refrattario. Lo studio di Fase 1 ha mostrato una sopravvivenza libera da progressione mediana di 30,2 mesi con un follow-up mediano di 38,1 mesi. Lo studio di Fase 2 iMMagine-1 ha dimostrato un tasso di risposta complessivo del 95% e un tasso di risposta completa del 62% in 58 pazienti con un follow-up mediano di 10,3 mesi. Non sono state osservate tossicità neurotossiche ritardate in oltre 140 pazienti trattati. L'azienda ha riportato 676,7 milioni di dollari in contanti e equivalenti, previsti per finanziare le operazioni fino al 2027. Le entrate da collaborazione del Q3 sono aumentate a 26,0 milioni di dollari, mentre la perdita netta è diminuita a 25,9 milioni di dollari.
Arcellx reportó los resultados financieros del tercer trimestre de 2024 y los avances clínicos para anito-cel en el tratamiento del mieloma múltiple recaído/refractario. El estudio de Fase 1 mostró una supervivencia libre de progresión mediana de 30,2 meses con un seguimiento mediano de 38,1 meses. El estudio de Fase 2 iMMagine-1 demostró una tasa de respuesta global del 95% y una tasa de respuesta completa del 62% en 58 pacientes con un seguimiento mediano de 10,3 meses. No se observaron neurotoxicidades tardías en más de 140 pacientes tratados. La compañía reportó 676,7 millones de dólares en efectivo y equivalentes, que se espera financien las operaciones hasta 2027. Los ingresos por colaboración del tercer trimestre aumentaron a 26,0 millones de dólares, mientras que la pérdida neta disminuyó a 25,9 millones de dólares.
Arcellx는 2024년 3분기 재무 결과와 재발성/내성 다발성 골수종 치료를 위한 anito-cel의 임상 진행 상황을 보고했습니다. 1상 연구에서는 30.2개월의 중앙 무진행 생존 기간과 38.1개월의 중앙 추적 관찰 기간이 나타났습니다. 2상 연구 iMMagine-1은 58명의 환자에서 10.3개월의 중앙 추적 관찰 기간 동안 95%의 전반적인 반응률과 62%의 완전 반응률을 보여주었습니다. 140명 이상의 치료를 받은 환자에서 지연된 신경독성이 관찰되지 않았습니다. 회사는 2027년까지 운영 자금을 지원할 것으로 예상되는 6억 7,670만 달러의 현금 및 현금성 자산을 보고했습니다. 3분기 협력 매출은 2,600만 달러로 증가했고, 순손실은 2,590만 달러로 감소했습니다.
Arcellx a annoncé les résultats financiers du troisième trimestre 2024 et les progrès cliniques d'anito-cel dans le traitement du myélome multiple en rechute/résistant. La première étude de phase a montré une survie sans progression médiane de 30,2 mois avec un suivi médian de 38,1 mois. L'étude de phase 2 iMMagine-1 a démontré un taux de réponse global de 95 % et un taux de réponse complète de 62 % chez 58 patients avec un suivi médian de 10,3 mois. Aucune neurotoxicité retardée n'a été observée chez plus de 140 patients traités. La société a annoncé 676,7 millions de dollars en liquidités et équivalents, qui devraient financer les opérations jusqu'en 2027. Les revenus de collaboration du troisième trimestre ont augmenté à 26,0 millions de dollars, tandis que la perte nette a diminué à 25,9 millions de dollars.
Arcellx berichtete über die Finanzergebnisse des dritten Quartals 2024 und den klinischen Fortschritt von anito-cel bei der Behandlung von rezidiviertem/refraktärem multiplem Myelom. Die Phase-1-Studie zeigte eine mediane progressionsfreie Überlebenszeit von 30,2 Monaten mit einer medianen Nachbeobachtungszeit von 38,1 Monaten. Die Phase-2-iMMagine-1-Studie demonstrierte eine Gesamtansprechrate von 95% und eine vollständige Ansprechrate von 62% bei 58 Patienten mit einer medianen Nachbeobachtungsdauer von 10,3 Monaten. Bei über 140 behandelten Patienten wurden keine verzögerten Neurotoxicitäten beobachtet. Das Unternehmen berichtete von 676,7 Millionen Dollar an Bargeld und Äquivalenten, die voraussichtlich die Betriebe bis 2027 finanzieren werden. Die Umsätze aus Kooperationen im dritten Quartal stiegen auf 26,0 Millionen Dollar, während der Nettoverlust auf 25,9 Millionen Dollar sank.
- Strong clinical efficacy with 95% overall response rate in Phase 2 study
- Favorable safety profile with no delayed neurotoxicities in 140+ patients
- Solid cash position of $676.7M funding operations into 2027
- Increased collaboration revenue to $26M, up from $15M YoY
- Reduced net loss to $25.9M from $39.3M YoY
- R&D expenses remain high at $39.2M despite decrease
- Increased G&A expenses by $4.5M to $20.5M
Insights
The clinical trial data for anito-cel shows remarkable efficacy in treating relapsed/refractory multiple myeloma. Key highlights include a
The safety profile stands out with no delayed neurotoxicities observed in over 140 patients, differentiating it from competing therapies. The manageable side effect profile, with mostly low-grade cytokine release syndrome, suggests potential for broad clinical adoption. The partnership with Kite for manufacturing adds significant commercial viability.
The company's financial position is robust with
The Kite partnership significantly de-risks commercialization by leveraging their established infrastructure and manufacturing capabilities. The strong clinical data positions anito-cel as a potential market leader in the lucrative multiple myeloma space.
-- Recently released ASH abstracts for the company’s Phase 1 and iMMagine-1 studies investigating anito-cel in relapsed or refractory multiple myeloma patients continue to demonstrate durability and a manageable safety profile --
-- 30.2-month median progression-free survival with a median follow-up of 38.1 months in the Phase 1 study of anito-cel; median overall survival not reached --
-- Preliminary results from 58 patients enrolled in the Phase 2 pivotal iMMagine-1 study demonstrated
-- No delayed neurotoxicities have been observed to date with anito-cel, including no parkinsonism, no cranial nerve palsies, and no Guillain-Barré syndrome across the Phase 1 and iMMagine-1 studies in the more than 140 patients dosed --
-- First patients dosed in iMMagine-3 study, manufactured by Kite; turnaround time in line with Kite’s commercial products --
“We believe the data from the recently published ASH abstracts continues to differentiate anito-cel’s clinical profile as a potentially best-in-class treatment option for multiple myeloma patients,” said Rami Elghandour, Arcellx’s Chairman and Chief Executive Officer. “The 30.2-month median progression-free survival demonstrated in our Phase 1 study in a challenging patient cohort coupled with the promising results from our iMMagine-1 Phase 2 registrational study highlight the potential impact we could have for patients. That impact is further enhanced by the high tolerability demonstrated through both the Phase 1 and iMMagine-1 studies to date, where notably, no delayed or non-ICANS neurotoxicities were observed in the over 140 patients treated to date. Patients and clinicians evaluate cell therapies on their safety, efficacy, delivery reliability, service, and accessibility. We believe we’re well positioned to deliver on these important factors in a differentiated way that best serves the multiple myeloma community. Our partnership with Kite allows us to leverage their established global commercial capabilities, positive brand recognition with physicians, and industry-leading manufacturing reliability and turnaround times which we believe contributes to our competitive advantage. It’s an exciting time at Arcellx! We are preparing for the commercial launch of anito-cel as there remains an unmet need for a therapy that physicians can use across a broad patient population.”
Recent Business Progress
Announced presentations at the 66th American Society for Hematology Annual Meeting and Exposition:
Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients With Relapsed and/or Refractory Multiple Myeloma: Preliminary Results From the iMMagine-1 Trial (abstract #1031)
As detailed in the abstract (#1031) as of June 1, 2024, 58 patients had received anito-cel infusion with ≥2 months of follow-up after infusion, with a median follow-up of 10.3 months (range, 2.0-17.8). The median age was 66 years (range, 38-77). Patients had received a median of four prior lines of treatment (range, 3-8) with 26 patients (
Investigator-assessed overall response rate (ORR) per International Myeloma Working Group (IMWG) criteria was
No delayed neurotoxicities, including no parkinsonism, no cranial nerve palsies, and no Guillain-Barré syndrome have been observed to date. Forty-six patients (
Conclusions
Preliminary results from the first 58 patients in the Phase 2 iMMagine-1 study demonstrate deep and durable responses and manageable safety in a high-risk fourth line or higher (4L+) RRMM population including triple- and penta-class refractory disease. Notably, no delayed neurotoxicities, including no cranial nerve palsies, Guillain-Barré syndrome, or Parkinsonian-like symptoms have been observed with anito-cel to date. Updated Phase 2 data with a more recent data cut will be presented at the oral presentation during ASH.
Presentation details:
Speaker: Ciara Freeman, M.D., Ph.D., H. Lee Moffitt Cancer Center
Session Name: 655. Multiple Myeloma: Cellular Therapies: Unleashing Cell Therapies Against Myeloma
Session Date: Monday, December 9, 2024
Session Time: 4:30 p.m. - 6:00 p.m.
Presentation Time: 5:30 p.m.
Location: Marriott Marquis San Diego Marina, Pacific Ballroom Salons 24-26
Publication Number: 1031
Submission ID: 198499
Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) (abstract #4825)
In the Phase 1 study, 40 patients were enrolled and 38 patients received anito-cel. All 38 patients demonstrated investigator-assessed clinical response per 2016 IMWG criteria, (ORR,
Presentation details:
Speaker: Michael R. Bishop, M.D., The University of
Session Name: 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities
Session Date: Monday, December 9, 2024
Presentation Time: 6:00 p.m. - 8:00 p.m.
Location:
Publication Number: 4825
Submission ID: 201080
Health Related Quality of Life (HRQoL) in Relapsed/Refractory Multiple Myeloma (RRMM): A Systematic Literature Review (SLR) and Meta-Analysis (abstract #4721)
Quantifying pre-treatment HRQoL burden is important as a reference for contextualizing baseline patient burden as emerging therapies for RRMM continue to evolve. This SLR synthesized studies that reported data for key multiple myeloma HRQoL instruments. It found that patients with RRMM had clinically meaningful impairments from population norms in important domains, such as Global Health Status and cognitive, physical, and emotional functioning. The SLR also found that pre-treatment HRQoL worsened with increasing lines of therapy.
Presentation details:
Speaker: Rahul Banerjee, M.D., Fred Hutchinson Cancer Center
Session Name: 653. Multiple Myeloma: Clinical and Epidemiological: Poster III
Session Date: Monday, December 9, 2024
Presentation Time: 6:00 p.m. - 8:00 p.m.
Location:
Treatment Patterns and Outcomes in Triple-Class Exposed Patients with Relapsed and Refractory Multiple Myeloma: Findings from the Flatiron Database (abstract #6962)
In order to understand the contemporary unmet need in the rapidly evolving treatment landscape for patients with triple-class exposed RRMM - those exposed to immunomodulatory drugs, proteasome inhibitors, and anti-CD38 monoclonal antibodies - in the 4L+ setting, a retrospective cohort study using the Flatiron Health electronic health record (HER) was conducted (sample size=594). This study found no clear standard of care in the 4L+ setting, and suboptimal health outcomes under the current treatment landscape (ORR=
First patients dosed in iMMagine-3, a global randomized Phase 3 study, assessing anito-cel in patients previously treated with both an immunomodulatory (IMiD) drug and an anti-CD38 monoclonal antibody. Kite is manufacturing for this study.
Third Quarter 2024 Financial Highlights
Cash, cash equivalents, and marketable securities:
As of September 30, 2024, Arcellx had cash, cash equivalents, and marketable securities of
Collaboration revenue:
Collaboration revenue were
R&D expenses:
Research and development expenses were
G&A expenses:
General and administrative expenses were
Net losses:
Net losses were
Upcoming Webcast Event:
Arcellx will host a live webcast event with an expert panel of clinicians on Monday, December 9, 2024, at 8:30 p.m. PT to discuss clinical results from its Phase 1 and iMMagine-1 trials. The event will be accessible from Arcellx’s website at www.arcellx.com in the Investors section. A webcast replay will be archived and available for 30 days following the event.
About Arcellx and Kite Collaboration
Arcellx and Kite, a Gilead Company, formed a global strategic collaboration and license agreement to co-develop and co-commercialize anito-cel for patients with relapsed or refractory multiple myeloma, RRMM. Anito-cel is currently being developed in a Phase 2 registrational pivotal study and a Phase 3 randomized controlled study for RRMM. Kite and Arcellx will jointly commercialize the anito-cel asset in
About Arcellx, Inc.
Arcellx, Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx believes that cell therapies are one of the forward pillars of medicine and Arcellx's mission is to advance humanity by developing cell therapies that are safer, more effective, and more broadly accessible. For more information on Arcellx, please visit www.arcellx.com. Follow Arcellx on X @arcellx and LinkedIn.
About iMMagine-3, A Global Randomized Controlled Phase 3 Study
iMMagine-3 is a Phase 3, global randomized controlled study designed to compare the efficacy and safety of anitocabtagene autoleucel (anito-cel) with SOC in patients with relapsed and/or refractory multiple myeloma (RRMM) who have received one to three prior lines of therapy, including an immunomodulatory drug (lMiD) and an anti-CD38 monoclonal antibody. iMMagine-3 will enroll approximately 450 adult patients. Prior to randomization, investigator’s choice of SOC regimens include: pomalidomide, bortezomib, and dexamethasone (PVd); daratumumab, pomalidomide, and dexamethasone (DPd); carfilzomib, daratumumab and dexamethasone (KDd); or carfilzomib and dexamethasone (Kd). Patients in the anito-cel arm will undergo leukapheresis and optional bridging therapy (with the SOC regimen selected by the investigator prior to randomization) followed by lymphodepleting chemotherapy (fludarabine 30 mg/m2/d and cyclophosphamide 300 mg/m2/d for 3 days) and one infusion of anito-cel (115×106 CAR+ T cells) on Day 1. The primary endpoint is progression free survival (PFS) per blinded independent review according to the 2016 IMWG uniform response criteria for MM with the hypothesis that anito-cel will prolong PFS compared to SOC. Key secondary endpoints include complete response rate (CR/sCR), minimal residual disease negativity, overall survival, and safety.
Forward-looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements in this press release that are not purely historical are forward-looking statements, including, without limitation, statements regarding: the best-in-class potential of anito-cel for patients suffering from multiple myeloma; the potential impact of anito-cel on rrMM patients; anito-cel tolerability and toxicity trends; Arcellx’s competitive positioning; Arcellx's plans for the research, pre-clinical and clinical development of its product candidates; the anticipated timing for the presentation of updated Phase 1 data and iMMagine-1 preliminary data; Arcellx’s partnership with Kite; the potential commercial launch of anito-cel, subject to FDA approval; Arcellx’s ability to deliver cell therapies that will meet the key expectations of patients and clinicians and serve the multiple myeloma community; and the sufficiency of cash, cash equivalents and marketable securities and its ability to fund operations into 2027. The forward-looking statements contained herein are based upon Arcellx's current expectations and involve assumptions that may never materialize or may prove to be incorrect. These forward-looking statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, including risks that may be found in the section entitled Part II, Item 1A (Risk Factors) in the Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, filed with the Securities and Exchange Commission (SEC) on or about the date hereof, and the other documents that Arcellx may file from time to time with the SEC. These forward-looking statements are made as of the date of this press release, and Arcellx assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
ARCELLX, INC. |
||||
SELECTED CONSOLIDATED BALANCE SHEET DATA |
||||
(in thousands) |
||||
|
|
|
||
|
September 30, |
December 31, |
||
|
2024 |
2023 |
||
Cash, cash equivalents, and marketable securities | $ |
676,682 |
$ |
729,185 |
Total assets |
|
764,909 |
|
825,132 |
Total liabilities |
|
281,891 |
|
339,752 |
Total stockholders' equity |
|
483,018 |
|
485,380 |
ARCELLX, INC. |
||||||||||||
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS | ||||||||||||
(in thousands, except share and per share amounts) | ||||||||||||
Three Months Ended September 30, |
Nine Months Ended September 30, |
|||||||||||
2024 |
2023 |
2024 |
2023 |
|||||||||
Revenue | $ |
26,030 |
|
$ |
14,957 |
|
$ |
92,670 |
|
$ |
47,171 |
|
Operating expenses: | ||||||||||||
Research and development |
|
39,173 |
|
|
43,807 |
|
|
112,444 |
|
|
105,065 |
|
General and administrative |
|
20,473 |
|
|
16,012 |
|
|
64,645 |
|
|
46,985 |
|
Total operating expenses |
|
59,646 |
|
|
59,819 |
|
|
177,089 |
|
|
152,050 |
|
Loss from operations |
|
(33,616 |
) |
|
(44,862 |
) |
|
(84,419 |
) |
|
(104,879 |
) |
Other income, net |
|
7,972 |
|
|
5,520 |
|
|
24,716 |
|
|
14,386 |
|
Loss before income taxes |
|
(25,644 |
) |
|
(39,342 |
) |
|
(59,703 |
) |
|
(90,493 |
) |
Income tax benefit (expense) |
|
(223 |
) |
|
6 |
|
|
(564 |
) |
|
(41 |
) |
Net loss |
|
(25,867 |
) |
|
(39,336 |
) |
|
(60,267 |
) |
|
(90,534 |
) |
Other comprehensive loss: | ||||||||||||
Unrealized gain (loss) on marketable securities |
|
2,691 |
|
|
(58 |
) |
|
1,352 |
|
|
156 |
|
Comprehensive loss | $ |
(23,176 |
) |
$ |
(39,394 |
) |
$ |
(58,915 |
) |
$ |
(90,378 |
) |
Net loss per share attributable to common stockholders—basic and diluted | $ |
(0.48 |
) |
$ |
(0.81 |
) |
$ |
(1.13 |
) |
$ |
(1.89 |
) |
Weighted-average common shares outstanding—basic and diluted |
|
53,821,893 |
|
|
48,348,094 |
|
|
53,367,256 |
|
|
47,777,446 |
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20241104768242/en/
Investor Contact:
Myesha Lacy
Arcellx, Inc.
ir@arcellx.com
510-418-2412
Media Contact:
Andrea Cohen
Sam Brown Inc.
andreacohen@sambrown.com
917-209-7163
Source: Arcellx, Inc.
FAQ
What were the key clinical results for ACLX's anito-cel in Q3 2024?
How much cash does ACLX have as of Q3 2024?
What was ACLX's collaboration revenue in Q3 2024?